Treace Medical Concepts, Inc. (TMCI) Tops Q2 EPS by 4c

Treace Medical Concepts, Inc. (NASDAQ: TMCI) reported Q2 EPS of ($0.20), $0.04 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $42 million versus the consensus estimate of $40.84 million.

GUIDANCE:

Treace Medical Concepts, Inc. sees FY2023 revenue of $191-197 million, versus the consensus of $194 million.

For earnings history and earnings-related data on Treace Medical Concepts, Inc. (TMCI) click here.

You May Also Be Interested In

• Rivian reports record Q3 deliveries, beats estimates, shares rise
• Cuprina to buy seven-clinic Singapore healthcare group for S$4M
• Integra LifeSciences cuts 2026 outlook after Cincinnati flood